104 related articles for article (PubMed ID: 3323994)
41. Prognostic significance of CA 125 and TPS levels after 3 chemotherapy courses in ovarian cancer patients.
van Dalen A; Favier J; Burges A; Hasholzner U; de Bruijn HW; Dobler-Girdziunaite D; Dombi VH; Fink D; Giai M; McGing P; Harlozinska A; Kainz C; Markowska J; Molina R; Sturgeon C; Bowman A; Einarsson R
Gynecol Oncol; 2000 Dec; 79(3):444-50. PubMed ID: 11104617
[TBL] [Abstract][Full Text] [Related]
42. [Tumor markers in epithelial carcinoma of the ovary].
Cottini M; Carnino F; Iskra L; Rapisarda V; Mossetti C
Minerva Ginecol; 1986 Jun; 38(6):479-84. PubMed ID: 3461313
[No Abstract] [Full Text] [Related]
43. [Principles of prevention, early detection, treatment and after care of ovarian cancer].
Ebeling K; Sarembe B
Zentralbl Gynakol; 1987; 109(9):553-67. PubMed ID: 3617994
[TBL] [Abstract][Full Text] [Related]
44. [Usefulness of CA.125 as a co-adjuvant test in the diagnosis and follow-up of ovarian cancer].
Hernández Briz MJ; Díaz Redondo A; Mújica Menéndez I; Merino Ramírez J; Crespo Azanza E; Fernández Villoria E; Sánchez Martín JA
Rev Clin Esp; 1986 Oct; 179(5):240-2. PubMed ID: 3466260
[No Abstract] [Full Text] [Related]
45. Harnessing the immune system for ovarian cancer therapy.
Odunsi K; Sabbatini P
Am J Reprod Immunol; 2008 Jan; 59(1):62-74. PubMed ID: 18154597
[TBL] [Abstract][Full Text] [Related]
46. [Prognostic value of CA 125 initial half-life measured during first-line chemotherapy in 62 patients with epithelial ovarian cancer stage III or IV].
Riedinger JM; Barillot I; Coudert B; Fargeot P; Berriolo-Riedinger A; Guerrin J
Bull Cancer; 1996 Aug; 83(8):654-63. PubMed ID: 8869046
[TBL] [Abstract][Full Text] [Related]
47. Diagnosis and management of ovarian cancer.
DiSaia PJ
Hosp Pract (Off Ed); 1987 Apr; 22(4):235-50. PubMed ID: 3104363
[No Abstract] [Full Text] [Related]
48. [A case of malignant ovarian granulosa cell tumor with poor prognosis].
Tokuoka S; Furuya K; Kita T; Kataoka Y; Ooyama S; Mizumoto Y; Kikuchi Y; Nagata I
Nihon Sanka Fujinka Gakkai Zasshi; 1995 Dec; 47(12):1393-6. PubMed ID: 8568363
[No Abstract] [Full Text] [Related]
49. [Comparative studies of the prognostic relevance of tumor markers in ovarian cancer].
Dörffler P; Caffier H
Gynakol Geburtshilfliche Rundsch; 1993; 33 Suppl 1():293-5. PubMed ID: 8118321
[No Abstract] [Full Text] [Related]
50. CA 125 in monitoring chemotherapy of the patients with ovarian cancer.
Markowska J; Kojczynski Z; Szewierski Z; Manys G
Eur J Gynaecol Oncol; 1990; 11(3):209-14. PubMed ID: 2209640
[TBL] [Abstract][Full Text] [Related]
51. Long-term follow-up of ovarian cancer with monthly determinations of serum CA 125.
Högberg T; Kågedal B
Gynecol Oncol; 1992 Aug; 46(2):191-8. PubMed ID: 1500022
[TBL] [Abstract][Full Text] [Related]
52. Prognostic value of CA 125 in advanced cancer.
Farghaly SA
Gynecol Oncol; 1992 Oct; 47(1):131-2. PubMed ID: 1427393
[No Abstract] [Full Text] [Related]
53. The value of the monoclonal antibody (cancer antigen 125) in serial monitoring of ovarian cancer: a comparison with circulating immune complexes.
Dodd J; Tyler JP; Crandon AJ; Blumenthal NJ; Fay RA; Baird PJ; Hicks LJ; Hudson CN
Br J Obstet Gynaecol; 1985 Oct; 92(10):1054-60. PubMed ID: 3863669
[TBL] [Abstract][Full Text] [Related]
54. Should we regard CA125 as the indication to treat relapsing ovarian cancer?
Fisken J; Leonard RC; Roulston JE
Ann Oncol; 1993 Mar; 4(3):257. PubMed ID: 8471561
[No Abstract] [Full Text] [Related]
55. Multimodality treatment warranted for ovarian cancer: immunotherapy, a prerequisite to improve prognosis for this vicious disease.
Leffers N; Daemen T; van der Zee AG; Nijman HW
Immunotherapy; 2009 Mar; 1(2):163-5. PubMed ID: 20635935
[No Abstract] [Full Text] [Related]
56. The bleak outlook on ovarian cancer.
Dugan KK
Am J Nurs; 1985 Feb; 85(2):144-7. PubMed ID: 2578735
[No Abstract] [Full Text] [Related]
57. [Therapy with biomodulators in ovarian cancer].
Nowotny C; Miksche M; Kölbl H; Gitsch G; Hanzal E; Szepesi T
Gynakol Rundsch; 1990; 30 Suppl 1():53-5. PubMed ID: 2127766
[No Abstract] [Full Text] [Related]
58. Ovarian cancer.
Richardson GS
JAMA; 1993 Mar; 269(9):1163. PubMed ID: 8433473
[No Abstract] [Full Text] [Related]
59. Immunotherapy for ovarian cancer: what are the targets of the future?
Adams SF; Benencia F
Future Oncol; 2015; 11(9):1293-6. PubMed ID: 25952776
[No Abstract] [Full Text] [Related]
60. [Ovarian cancer: treatment by specific neuraminidase].
Dodin A; Zylberberg B
Nouv Presse Med; 1979 Feb; 8(6):437. PubMed ID: 554105
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
